Petrichor supports world-class healthcare managers and businesses.
Our platform spans company formation through late-stage and commercial growth opportunities with a long-term and strategic approach.
Petrichor maintains a deep in-house understanding of scientific, technical, and commercial expertise to create, identify and support the next generation of healthcare innovation.
Petrichor supports world-class healthcare managers and businesses.
Our platform spans company formation through late-stage and commercial growth opportunities with a long-term and strategic approach.
Petrichor maintains a deep in-house understanding of scientific, technical, and commercial expertise to create, identify and support the next generation of healthcare innovation.
Capital to drive scientific and medical innovation
Petrichor was launched in 2018 to support world-class healthcare managers and businesses with customized investment structures and support. Our platform spans company formation through late-stage growth opportunities with a consistent long-term and strategic approach.
Petrichor maintains a deep in-house understanding of biopharmaceutical and medical technology products and services. This scientific, technical, and commercial expertise helps us identify and actively facilitate the next generation of healthcare innovation.
Petrichor Capital Partners
Petrichor Capital Partners provides structured investments to support the development and commercial growth of innovative biopharmaceuticals, medical technologies, and services poised to transform the healthcare landscape. Our deep industry expertise creates portfolio relationships beyond capital, helping private or public companies around the world achieve their growth potential.
Scion Life Sciences
Scion Life Sciences is a venture capital fund dedicated to founding and building exceptional biotechnology companies that discover, develop and seek to commercialize clinically transformational or curative new medicines. We are a team of experienced innovators, company-builders and investors committed to meaningfully improving human health. We have no interest in the incremental and measure ourselves by the clinical impact of the companies we build and the therapies we create.
